In recent trading, shares of Hims & Hers Health Inc (Symbol: HIMS) have crossed above the average analyst 12-month target price of $20.50, changing hands for $22.77/share. When a stock reaches the ...

Hims & Hers stock price continues to fire on all cylinders this year and is hovering near its highest level on record. It has ...

Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo ...

The companies will sell the drug at a reduced price of $499 a month. Consumers looking to start the popular weight loss drug Wegovy but lacking insurance coverage will soon have a new option. Novo ...

Hims & Hers Health is now reasonably valued after its large drop, making it a cautious Buy due to its high-growth potential. The company's revenue grew 69% YoY to $1.5 billion, driven by a 45% ...

The move will rapidly expand Hims & Hers’ reach, which has a current base of 2.4 million U.S. customers. As the only digital health company with over a decade of operations across Germany, France, ...

Hims & Hers Health (HIMS) has seen its stock climb steadily, jumping 39% in the past month. This upward trend is catching attention, with investors curious about what is fueling the company’s ongoing ...

Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company’s scalable model, product launches, and global expansion plans ...

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...